USPTO serial 97593502
SLOREL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 8, 2025
- Examiner
- SAXTON, EVELYN H
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SLOREL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Gyeonggi-do, KR
Gyeonggi-do, KR
SEOUL, KR
SEOUL, KR
Gyeonggi-do, KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Caroline E. Bryce
Caroline E. Bryce SHERIDAN ROSS P.C.1560 BROADWAY, SUITE 1200DENVER, CO 80202United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Surgical implants comprised of living tissues for guided tissue regeneration; implants comprising living tissue; implantable materials for use in guided tissue regeneration in the nature of implants comprising living tissue; Surgical implants comprised of living tissues used in transplants, namely, vascular grafts being living tissue and human allograft tissue; surgical implants comprised of living tissues; human allograft tissue; bone void fillers comprised of living tissues; Stem cells for medical purposes, namely, surgical implants grown from stem cells; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for tissue regeneration; medicines for human purposes, namely, pharmaceutical preparations for the treatment of musculo-skeletal disorders; medicines for human purposes, namely, a drug delivery system comprising liquids, powders, tablets or capsules for the continuous release of a wide variety of therapeutic agents, namely, pharmaceutical preparations for the treatment of musculo-skeletal disorders; drugs for medical purposes, namely, drugs for use in bioregenerative procedures, drugs for use for regenerative purpose, drugs for use to assist with artificial bone growth, drugs for use in accelerating bone formation, drugs for use to stimulate new bone formation; pharmaceutical agents affecting sensory organs; pharmaceutical preparations for the prevention of diseases of the musculo- skeletal system; pharmaceutical preparations for the treatment of Musculo-skeletal disorders; cellular function activating agents for medical purposes; pharmaceutical preparations for use in organ transplantation; biological tissue cultures for medical purposes; drug delivery agents in the form of liquid, powders, tablets and capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films added to bone substitutes that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films for use in bioregenerative procedures that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that provide sustained release of drugs for use with implants and bone substitutes that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of drug delivery compounds that facilitate sustained or extended release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films with controlled timing and rate of drug release that facilitate the delivery of pharmaceutical preparations; medicines for human use, namely pharmaceutical preparations for the treatment of musculo-skeletal disorders featuring controlled timing and rate of release; medical bone graft substitute, namely, biological tissue bone grafts; medical bone graft materials, namely, bone fillers consisting of living materials; medical bone graft materials with drug release function being bone growth media consisting of biological materials for medical bone graft purposes with drug release function; medical bone graft materials, namely, biological bone tissue intended for subsequent implantation in a bone graft with drug release function, that provide sustained release of drugs for use with implants and bone substitutes; medical bone graft materials being biological bone tissue intended for subsequent implantation with drug release function that are sold filled with pharmaceutical preparations, namely, biological growth factors, used with implants and bone substitutes; medical bone graft materials being biological bone tissue intended for subsequent implantation with drug release function that are sold filled with pharmaceutical preparations, namely, antibiotics, used with implants and bone substitutes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CG Bio Co., Ltd.
- Other trademarks owned by CG Bio Co., Ltd.
- Other trademarks owned by A1 CO., LTD.
- Other trademarks owned by CG BIO CO., LTD.
- Other trademarks owned by CG Bio Co., Ltd.
- Other trademarks in Class 005
- Similar marks named SLOREL
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 21, 2026 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Oct 21, 2026 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jul 8, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 8, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 20, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 20, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 14, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 17, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 14, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 14, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 14, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 8, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 8, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 8, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 17, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 12, 2024 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Dec 12, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 12, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 12, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 12, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 12, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 6, 2024 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Nov 6, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 6, 2024 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Nov 6, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 6, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 6, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 6, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 5, 2024 | ALIE | ASSIGNED TO LIE | — |
| Aug 13, 2024 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Mar 12, 2024 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jan 17, 2024 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jun 16, 2023 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jun 16, 2023 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jun 16, 2023 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 12, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 12, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 12, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 14, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 14, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 14, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 14, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 1, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 19, 2022 | NWAP | NEW APPLICATION ENTERED | — |